I though this was a very well
written article, describing a thorough and calculated experimental procedure
and its results. The introduction clearly laid out the issues in developing new
therapeutics for depression and how this is potentially related to the
under-study of microglia, despite signs of microglial abnormality in depressive
patients and other neurological disease. This laid out a good framework for why
the study was conducted and what it hoped to achieve.
Within the materials and methods
section, I was slightly confused as to why the behavioral tests were performed
during the dark phase in the light dark cycle. Would removing the animals from
the dark room and moving them to a bright testing room not influence their
circadian rhythms in way that could act as a confounding variable? I am also
curious as to if there was any variability in results between the different CUS
paradigms. Tilting the cage seems to be significantly less extreme than
exposing the rats to a strobe light or water deprivation. The accuracy of the
behavioral measurements in assessing degree of depressive symptoms in rodents
would also interest me. I know that it is hard to diagnose a mouse with
depression, but it seems like many other factors could be influencing changes
in social exploration or the open field test for example. The pharmacological
interventions used were initially confusing but made more sense once they were
discussed in the results section and the purpose of each administration was
discussed in more detail.
The localization of decreased
microglia was interesting, it does make sense that there would be no
significant difference in the somatosensory cortex, as depression generally
does not seem to influence sensory perception. Also, as there was a strong
negative correlation between microglial expression and anhedonia it would be
interesting to use this data to see if certain CUS paradigms are more effective
than others. I was impressed at how the minocycline and imipramine were used to
provide evidence that it is the initial microglial activation that leads to the
eventual microglial apoptosis. This extra step really solidifies the results of
the study.
Overall, I think that this article
addressed two important and interesting issues within the field of Neuroscience:
the oversimplification of glial cell function as well as the multifaceted and
complicated etiology of depression. It provides strong evidence for stress
induced increase in microglial activity leading to later microglial apoptosis,
correlated with depressive behavior. In addition to this the article introduces
GM-CSF as a treatment which increased microglial proliferation and reversed
depressive symptoms in terms of sucrose preference. Given these results, I was
surprised that the article was published in 2014 but this was the first time I
heard anything about the issues discussed. While I don’t actively read
scientific literature about the neuroscience of depression, I would have
expected the information from the article to come up in some of the psychology
or BNS classes I have taken. It seems that depression is discussed to some
extent in every psych and neuro class I have taken but usually just in
relationship to serotonin. I am also aware that it takes extremely long for
clinical therapeutics to be developed from animal studies, but I am interested
if there are any projects in the works.
Agreed about testing during the dark cycle--often investigators want to assess behavior during the rodent's active phase (dark), but moving them through the hallways, etc could be problematic. My guess is the behavior rooms themselves were also dark/lit with red light. Glad this introduced you on to the immune signaling story of depression!
ReplyDelete